Platform Rational

LiPlasome Pharma’s drug delivery platform consists of:

A lipid based drug delivery system (LiPlasomes) for the intravenous transportation of anticancer drugs and prodrugs. The delivery system is formulated with polyethylene glycol (PEG) to prolong the serum half-life of the drugs and prodrugs and avoid the nanocarriers being removed by the reticuloendothelial system (RES).

An activating release mechanism ensures that the prodrugs and drugs are released specifically at the tumor target site. The triggered activation in the cancer tissue is based on an endogenous lipid degrading enzyme, secretory phospholipase A2 (PLA2), which is present in high concentrations in all human solid tumors investigated to date. Examples include prostatic, pancreatic, colorectal, gastric, and breast tumors.

Our innovative prodrug and drug delivery concept is very flexible and allows for the incorporation of different conventional cancer chemotherapeutics as well as new anticancer prodrugs that are designed on basis of the company’s proprietary drug discovery platform.